Core Viewpoint - New Nuo Wei's stock price has shown volatility, with a year-to-date increase of 21.98% but a significant decline of 33.69% over the past 60 days, indicating potential market concerns and investor sentiment shifts [1][2]. Financial Performance - For the period from January to September 2025, New Nuo Wei reported a revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71%. However, the net profit attributable to shareholders was a loss of 24.049 million yuan, a decrease of 117.26% compared to the previous year [2]. - Since its A-share listing, New Nuo Wei has distributed a total of 651 million yuan in dividends, with 500 million yuan distributed over the last three years [3]. Shareholder and Market Activity - As of October 31, 2025, the number of shareholders for New Nuo Wei increased by 32.87% to 21,800, while the average number of circulating shares per person decreased by 24.74% to 57,116 shares [2]. - The stock has experienced significant trading activity, with a net outflow of 1.7647 million yuan in principal funds on November 19, 2025, and a notable presence on the trading leaderboard with a net buy of 39.7092 million yuan on June 6, 2025 [1]. Institutional Holdings - As of September 30, 2025, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 17.7822 million shares, a decrease of 3.2169 million shares from the previous period. Other notable shareholders include various mutual funds, with some increasing and others decreasing their holdings [3].

Core Viewpoint - Fujian Pharmaceutical Co., Ltd. has experienced significant stock price increases this year, with a 120.14% rise year-to-date and a 25.93% increase in the last five trading days, indicating strong market interest and potential investment opportunities [1][2]. Financial Performance - For the period from January to September 2025, Fujian Pharmaceutical reported a revenue of 769 million yuan, a year-on-year decrease of 21.24%, and a net profit attributable to shareholders of -62.75 million yuan, a slight decrease of 1.09% [2]. - The company has cumulatively distributed 359 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 19, the stock price reached 18.36 yuan per share, with a trading volume of 502 million yuan and a turnover rate of 6.20%, resulting in a total market capitalization of 9.89 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on November 17, where it recorded a net buy of -40.63 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.87% to 20,700, while the average circulating shares per person increased by 5.59% to 21,347 shares [2].

Macro Research - The growth rate of national general public budget revenue increased by 0.8% year-on-year from January to October 2025, with a marginal recovery in October to 3.2% compared to 2.6% in September, primarily driven by tax revenue [3][4] - The decline in non-tax revenue has expanded, reflecting a reduced reliance on non-tax income by the government [4] - National general public budget expenditure grew by 2% year-on-year from January to October 2025, with a significant drop in October to -9.8% compared to 3.1% in September, indicating a need for continued fiscal support to stabilize the economy [4][5] Fixed Income Research - The global monetary and fiscal system has undergone significant changes since 2008, which may provide more relevant insights for predicting domestic economic and fixed income asset trends than historical experiences from the 1990s [7][8] - The government’s increasing leverage has not led to a corresponding rise in household and corporate leverage, resulting in a rapid increase in interest rates independent of the recovery in these sectors [8] Transportation Research - The short-term profitability of the company is under pressure due to maintenance impacts, but the high-quality route network is expected to reveal significant profit elasticity, with a projected increase in profitability driven by rising ticket prices and fleet turnover recovery in the next two years [10][11] - The company’s net profit for the first three quarters of 2025 was 1.09 billion yuan, a year-on-year decrease of 14%, primarily due to maintenance impacts [10][11] Communication Research - The company maintained its profit forecast but lowered its target price while keeping a buy rating, as the Q4 performance is expected to rebound despite short-term fluctuations [13][14] - The company achieved a revenue of 16.5 billion yuan in the first three quarters of 2025, a year-on-year increase of 221.7%, with a net profit of 6.33 billion yuan, reflecting strong growth despite a slight decline in Q3 [14]

Core Viewpoint - The company Zhongsheng Pharmaceutical (002317.SZ) has announced that its drug Angladiwei tablets (brand name: Anruiwei®) is effective for treating adult patients with uncomplicated influenza A, showing strong inhibitory activity against various influenza virus strains, including those resistant to Oseltamivir and Baloxavir [1] Company Summary - The Angladiwei tablets are specifically indicated for adult patients with uncomplicated influenza A [1] - Preclinical research indicates the drug's effectiveness against multiple influenza virus strains, including highly pathogenic avian influenza and resistant strains [1]

Group 1 - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., will hold its third extraordinary general meeting of shareholders on December 5, 2025, as decided in the 24th meeting of the fifth board of directors [1][31] - The meeting will combine on-site voting and online voting, with specific time slots for each voting method [2][3] - Shareholders must register to attend the meeting between December 2 and December 3, 2025, and can delegate representatives to vote on their behalf [11][12] Group 2 - The board of directors has approved the termination of the 2025 restricted stock and stock option incentive plan due to the company's inability to complete the necessary registration and announcement within the stipulated 60 days [27][35] - The decision to terminate the incentive plan was made after considering the current operational situation and market conditions, ensuring it does not negatively impact the company's financial status or shareholder interests [36][37] - The company will not propose a new incentive plan for three months following the announcement of the termination [36]

格隆汇11月19日丨众生药业(002317.SZ)在投资者互动平台表示，公司的昂拉地韦片（商品名：安睿威 ®）适用于成人单纯性甲型流感患者的治疗，临床前研究结果表明，对包括奥司他韦耐药株、高致病性 禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感病毒株具有强大的抑制活性。 ...

Core Viewpoint - The company announced its profit distribution plan for the first three quarters of 2025, detailing a cash dividend of 0.147 yuan per share, which represents 29% of the net profit attributable to shareholders for the same period [2][5][9]. Distribution Plan - The distribution year is set for the first three quarters of 2025 [4]. - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [4]. - The total number of shares eligible for distribution is 432,334,800 shares after excluding shares held in the company's repurchase account [5]. Dividend Details - The company plans to distribute a total cash dividend of 63,553,215.60 yuan (including tax) [5]. - The cash dividend distribution will not include stock dividends or capital reserve transfers [5]. - The cash dividend per share is calculated as approximately 0.1460 yuan after adjustments [7]. Taxation Information - For individual shareholders, the tax treatment varies based on the holding period of the shares, with a maximum tax rate of 20% for shares held for one month or less [9][10]. - Qualified Foreign Institutional Investors (QFIIs) will have a withholding tax of 10%, resulting in a net cash dividend of 0.1323 yuan per share [11]. - Hong Kong investors will also face a 10% withholding tax, with similar provisions for tax treaty benefits [12]. Implementation Method - Shares held in the company's repurchase account will not participate in the profit distribution [8]. - Cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [7].

Core Points - The company held its first extraordinary general meeting of shareholders on November 18, 2025, where all resolutions were approved without any objections [2][4][12] - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][8] - The company decided to abolish the supervisory board and amend its articles of association accordingly, which was passed as a special resolution [4][12] Meeting Attendance - All 9 current directors and 3 supervisors attended the meeting, along with the board secretary and senior management [3][8] - The meeting was chaired by the company's chairman, Zheng Zhiguo [2][8] Resolutions Passed - The following amendments to internal management systems were approved: - Abolishment of the supervisory board and revision of the articles of association [4][12] - Amendments to various internal management rules, including shareholder meeting rules, board meeting rules, independent director work system, external investment management system, related party transaction management system, fundraising management system, external guarantee management system, financial derivatives trading internal control system, investor relations management system, major information internal reporting system, and information disclosure system [5][6] - The resolutions received more than two-thirds approval from the voting shareholders [6] Legal Verification - The meeting was witnessed by Beijing Hairun Tianrui Law Firm, confirming that the meeting's procedures and voting results were legal and valid [6][12] Board Meeting - The fourth board meeting was held on the same day, November 18, 2025, with all 9 directors present [8][9] - The board confirmed the members and convener of the audit committee, ensuring compliance with relevant laws and regulations [9][10] Employee Representative Director - The company elected Liu Yu as the employee representative director, replacing Xu Haiyan, with his term aligned with the current board's term [12][13] - Liu Yu meets the qualifications for the position as stipulated by the Company Law and the company's articles of association [13]

Core Viewpoint - Han Yu Pharmaceutical has undergone significant management changes, appointing two new executive presidents to adapt to a complex market environment and pursue internationalization strategies [2][3][4]. Management Changes - The resignation of PINXIANG YU, the former executive president, was due to retirement, and he will not hold any positions in the company or its subsidiaries post-resignation [3]. - The board has appointed Tang Yangming and Shen Yaping as new executive presidents, with their terms lasting until the current board's term ends [3][4]. - Tang Yangming has over 20 years of experience in peptide drug research and has been with Han Yu Pharmaceutical since 2005 [3]. - Shen Yaping, an external hire, has a notable background in international business from his tenure at Jiangsu Hengrui Medicine Co., Ltd., where he held various senior roles [4]. Recent Personnel Adjustments - Han Yu Pharmaceutical has made multiple personnel adjustments in the second half of the year, affecting key positions such as vice presidents, board secretaries, and committee members [5][6]. - The company has seen a rapid succession of management changes, including the resignation of vice president Zhang Baole and board secretary Yang Di, both of whom left for personal reasons [6]. Financial Performance - In the first three quarters of the year, Han Yu Pharmaceutical reported a revenue of 683 million yuan, marking an 82.06% year-on-year increase, and a net profit of 71.35 million yuan, indicating a turnaround from losses [7]. - The company achieved an operating cash flow of 271 million yuan, a significant increase of 207.37%, setting a historical high for the same period [7].

Core Viewpoint - Fuxiang Pharmaceutical (300497) is planning to increase its VC product production capacity from 8,000 tons per year to 10,000 tons per year by the second quarter of 2026 through technological upgrades [1] Group 1 - The current production capacity of VC products is 8,000 tons per year [1] - The company aims to complete the capacity upgrade to 10,000 tons per year by Q2 2026 [1] - Future capacity expansion to 20,000 tons per year will depend on market demand and industry capacity release [1]